(IYH) iShares U.S. Healthcare - Ratings and Ratios
Pharmaceuticals, Biotech, Medical Devices, Health Services
Dividends
| Dividend Yield | 0.80% |
| Yield on Cost 5y | 1.14% |
| Yield CAGR 5y | -29.01% |
| Payout Consistency | 92.1% |
| Payout Ratio | - |
| Risk via 5d forecast | |
|---|---|
| Volatility | 11.9% |
| Value at Risk 5%th | 19.6% |
| Relative Tail Risk | 0.33% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.53 |
| Alpha | 2.21 |
| CAGR/Max DD | 0.36 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.338 |
| Beta | 0.510 |
| Beta Downside | 0.533 |
| Drawdowns 3y | |
|---|---|
| Max DD | 17.91% |
| Mean DD | 5.21% |
| Median DD | 3.83% |
Description: IYH iShares U.S. Healthcare November 09, 2025
The iShares U.S. Healthcare ETF (IYH) is an exchange-traded fund that commits at least 80 % of its net assets to the securities comprising its benchmark index, which tracks the performance of the U.S. healthcare equity sector. Because it holds a concentrated set of stocks, the fund is classified as non-diversified under SEC rules.
Key metrics that investors often monitor for IYH include its expense ratio of 0.43 % (below the average for sector ETFs), a top-10 holdings concentration of roughly 45 % (dominated by large-cap firms such as UnitedHealth Group, Johnson & Johnson, and Pfizer), and a dividend yield near 1.2 % as of the latest quarter. The sector’s growth drivers are the aging U.S. population, rising chronic-disease prevalence, and sustained federal and private R&D spending-factors that historically generate a secular earnings tailwind for healthcare providers, biotech innovators, and medical-device manufacturers.
For a deeper, data-driven view of how IYH’s risk-adjusted performance stacks up against peers, you might explore the analytics platform ValueRay, which offers granular, real-time metrics to help you validate the ETF’s expected value under different market scenarios.
What is the price of IYH shares?
Over the past week, the price has changed by +1.12%, over one month by -1.15%, over three months by +15.46% and over the past year by +12.52%.
Is IYH a buy, sell or hold?
What are the forecasts/targets for the IYH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 69 | 5.1% |
IYH Fundamental Data Overview December 23, 2025
Beta = 0.61
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 3.57b USD (3.57b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 3.57b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 3.57b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 7.90% (E(3.57b)/V(3.57b) * Re(7.90%) + (debt-free company))
Discount Rate = 7.90% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for IYH ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle